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Background. Exposuretoenvironmentalchemicalsmayimpairendocrinesystemfunction.AlaskaNative(AN)
women may be at higher risk of exposure to these endocrine disrupting chemicals, which may contribute to
breast cancer in this population.
Objective. To measure the association between exposure to select environmental chemicals and breast cancer
among AN women.
Design. A case control study of 170 women (75 cases, 95 controls) recruited from the AN Medical Center
from 1999 to 2002. Participants provided urine and serum samples. Serum was analyzed for 9 persistent
pesticides, 34 polychlorinated biphenyl (PCB) congeners, and 8 polybrominated diethyl ether (PBDE)
congeners. Urine was analyzed for 10 phthalate metabolites. We calculated geometric means (GM) and
compared cases and controls using logistic regression.
Results. Serum concentrations of most pesticides and 3 indicator PCB congeners (PCB-138/158; PCB-153,
PCB-180) were lower in case women than controls. BDE-47 was significantly higher in case women
(GM 38.8 ng/g lipid) than controls (GM 25.1 ng/g lipid) (p 0.04). Persistent pesticides, PCBs, and most
phthalate metaboliteswere not associatedwith case status inunivariate logistic regression. The odds of being a
case were higher for those with urinary mono-(2-ethylhexyl) phthalate (MEHP) concentrations that were
above the median; this relationship was seen in both univariate (OR 2.16, 95% CI 1.16 4.05, p 0.02) and
multivariable (OR 2.43, 95% CI 1.13 5.25, p 0.02) logistic regression. Women with oestrogen receptor
(ER) /progesterone receptor (PR)-tumour types tended to have higher concentrations of persistent pesticides
than did ER /PR women, although these differences were not statistically significant.
Conclusions. Exposure to the parent compound of the phthalate metabolite MEHP may be associated with
breast cancer. However, our study is limited by small sample size and an inability to control for the
confounding effects of body mass index. The association between BDE-47 and breast cancer warrants further
investigation.
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ancer is the leading cause of death among Alaska
Native (AN) men and women (1). Breast cancer is
among the most frequently diagnosed cancers in
this population; from 2004 to 2008, breast cancer ac-
counted for 14% of all cancer deaths among AN women
(2). In the 40 years between 1969 and 2008, the incidence
of breast cancer among AN women tripled (2). Although
breast cancer rates of AN women have been lower than
that of US white women, the rates are now similar (2).
Exposure to organochlorine pesticides and polychlori-
nated biphenyls (PCBs), polybrominated diethyl ethers
(PBDEs), and phthalates (collectively referred to here as
environmental chemicals) may impair the normal func-
tioning of the endocrine system (3). Organochlorine
pesticides and PCBs in particular have been studied for
their association with breast cancer incidence, with con-
flictingresults(4 16).In2006,Rubinetal.conductedapi-
lotstudyevaluatingtherelationshipbetweenbreastcancer
andconcentrationsofp,p?-dichlorodiphenylethylene(DDE),
a metabolite of dichlorodiphenyltrichloroethane (DDT),
and PCBs among AN women. The results showed ubiq-
uitous exposure to a number of persistent chemicals at
levelssimilartothosereportedinthecontiguousUSstates.
The study reported slightly higher levels of DDE, but
slightlylowerlevelsofPCBsamongANwomendiagnosed
with breast cancer compared to women who were not
diagnosed with breast cancer. However, this relationship
was not statistically significant when controlling for the
risk factors such as diet, ethnicity, and geographic region
of residence. Some studies reported an association be-
tweenbreastcancerandDDEexposure(7 9),whileothers
reported no association (10 14). Similarly, studies of
breast cancer and exposure to PCBs reported conflicting
results (7 9,12,15,16).
PBDEs have demonstrated endocrine disrupting cap-
abilities in animal and in vitro studies (17 20). The PBDE
congener BDE-47 is consistently detectable and at higher
concentrations than other BDE congeners in human, ani-
mal, and environmental samples. A recent case control
study was conducted to determine whether risk of breast
cancer was associated with concentrations of PBDE con-
geners measured in adipose tissue. No association was
found (21). Phthalates have also demonstrated possible
hormone-disrupting properties, although the human
health effects of chronic low-dose exposure to phthalates
are currently unknown (22). Only one study was found
that examined the association between exposure to
phthalates and breast cancer, and reported a positive
association between urinary concentrations of monoethyl
phthalate (MEP) and breast cancer (23).
AN populations may be at higher risk for exposure to
certain environmental chemicals for a number of reasons.
Organochlorine pesticides and PCBs resist degradation
and persist in the environment. Marine animals caught
in the Arctic, a large part of a traditional AN diet, are
reported to have higher concentrations of synthetic
persistent organic pollutants (4,24,25) than their southern
counterparts as a result of atmospheric and oceanic
transport and deposition of environmental chemicals in
the Arctic (26).
Technical pentaBDE containing PBDE congeners with
3 6 bromine atoms were added to consumer products
such as furniture cushions andwall-to-wall carpet pads to
decrease flammability. Technical octa- and decaBDE with
higher degrees of bromination were used in hard plastics,
such as casings for electrical appliances. The predominant
routes of human exposure to PBDE mixtures are inges-
tion and/or inhalation of indoor residential dust and
ingestion of food containing these chemicals (27). For
AN people who consume foods comprising a traditional
diet, ingesting food containing these chemicals is quanti-
tatively a more important route of exposure than for the
general US population.
Added to common household, personal care, medical,
and commercial products, human exposure to phthalates
is ubiquitous in the United States (22). Unlike the other
environmental chemicals discussed here, phthalates do
not persist in the environment and do not bioaccumulate
(22,28). Although phthalates are easily metabolized and
excreted in the urine, their pervasiveness and potential
hormone-disrupting effects present a concern for chronic
low-dose exposure (28).
The objective of this study was to investigate possible
associationsbetweenbreastcanceramongANwomenand
concentrations of select environmental chemicals mea-
sured at the time of enrolment. A strength of this study is
the use of pre-treatment samples to quantify chemical
exposures. To determine whether different types of tu-
mours have different risk factors, we examined differences
in concentrations of environmental chemicals in women
with oestrogen receptor (ER) and progesterone receptor
(PR) positive and ER/PR-negative tumours. We discuss
environmentalchemicalsmeasuredinserum(organochlor-
ine pesticides, PCBs, and PBDEs) and urine (phthalate
metabolites) collected at enrolment in relation to demo-
graphic characteristics, health history information, and
breast tissue pathology, including ER/PR status.
Methods
Screening and enrolment
The protocol for this study was reviewed and approved
by the Institutional Review Boards (IRB) of the Alaska
Area and the US Centers for Disease Control and
Prevention (CDC). We invited women who presented to
the Alaska Native Medical Center (ANMC) in Ancho-
rage, Alaska for excisional breast biopsy, lumpectomy,
mastectomy, or breast reconstruction between March
1999 and March 2002 to enrol in this study. Consenting
participants could take part in one or more of the study’s
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and analysis; and analysis of banked serum collected
from participants during previous studies. Participants
could withdraw from the study at any time, and were not
provided personal results; only aggregated data were
provided to participants. ANMC physicians did not
know if their patients were enrolled in this study to
prevent any real or perceived conflict of interest in
healthcare delivery. We did not collect data about reasons
for refusal to participate.
A case was defined as an enrolled participant whose
surgical procedure resulted in a diagnosis of invasive or
in situ breast cancer based on ANMC pathology results.
Following department guidelines, biopsies with invasive
cancer,orinitialbiopsieswhereinvasioncouldnotberuled
out, were sent to a contract laboratory to be analyzed for
ER and PR status. A control was defined as an enrolled
participant whose tissue analysis was returned from
pathology without a cancer diagnosis. All control women
had diagnoses of benign breast conditions, such as
fibrocystic changes and hyperplasia; none had lesions
suspicious for cancer. Women receiving only core needle
biopsywereexcludedfromthestudybecausetheprocedure
did not yield sufficient tissue for analysis.
Biologic specimen collection
Blood and urine samples were obtained by the study’s
research nurse in the surgery outpatient clinic during a
pre-operative surgery clinic visit. Blood samples were
obtained by venipuncture and collected in a 10 ml plain
red-top Vacutainer tube. The ANMC laboratory sepa-
rated serum from blood cells and placed the serum in
glass vials, which were stored frozen at CDC Arctic
Investigations Program (AIP). Urine samples were col-
lected in glass and frozen within 2 hours of collection.
Biologic specimens were matched to the study partici-
pant by their unique identification number. To limit
potential incidental contamination with chemicals of
interest to the study, at no time were enrolment serum
or urine samples collected or stored in plastic vials. All
glass receptacles were provided by the National Center of
Environmental Health’s (NCEH) Division of Laboratory
Sciences (DLS) at CDC in Atlanta, Georgia. All samples
collected at the time of enrolment were frozen, batched,
packaged and shipped by CDC AIP to CDC DLS at
intervals throughout the enrolment period.
Participant interview
Participants were interviewed for demographic and risk
factor information, and dietary, pregnancy, and residence
histories. Patient information was recorded on paper
forms identified only by the participant’s unique study ID
number. Completed questionnaires containing no perso-
nal identifying information were mailed to the primary
investigator at CDC NCEH where data were entered and
stored in a secure electronic database.
Laboratory analysis
Serum samples collected at enrolment were analyzed
for a number of environmental chemicals, including 9
persistent pesticides (including 2 metabolites of DDT), 34
PCB congeners, and 8 PBDE congeners (29). Urine sam-
ples were analyzed for 10 phthalate metabolites (30).
Concentrations of chemicals measured in serum are lipid-
adjusted; concentrations of phthalate metabolites mea-
sured in urine are creatinine corrected. All laboratory
analyses were completed by fall 2004.
Data analysis
AllstatisticalanalyseswereconductedusingSAS9.1.PCB
and pesticide concentrations were normalized by natural
log transformation. Concentrations below the limit of
detection (LOD) were assigned a value equal to the
LOD divided by the square root of 2 (31). Geometric
means (GM) were calculated for persistent pesticides,
indicator PCBs, and BDE-47 measured in serum, and for
7 phthalate metabolites measured inurine. We report only
the indicator PCBs and BDE-47 because they are the
congeners most frequently found in serum and usually at
the highest concentrations. These congeners are reported
widelyintheliteratureasindicatorsofexposuretoPBDEs
andPCBs.TheindicatorPCBcongenersselectedarethose
fromdietarysources.Threeofthe10phthalatemetabolites
were detectable in fewer than 60% of the samples analyzed
and were excluded from the analysis. GM concentrations
were compared between cases and controls and between
oestrogen-positive/progesterone-positive (ER /PR )
and oestrogen-negative/progesterone-negative (ER /PR )
cases by t-tests. Chi-square tests were used to compare
categorical risk factors between cases and controls and
betweenER /PR andER /PR  tumour types incases.
The demographic variables, ‘‘place of birth’’ and
‘‘current residence,’’ were categorized into 5 recognized
regions of the state: northwest, southwest, south central,
interior, and southeast Alaska. Ethnicity was based on
self-report at interview   participants were categorized as
Eskimo, Indian, or Aleut. Study participants who were
American Indian of non-Alaskan origin were categorized
as ‘‘other.’’
Logistic regression was used to explore the association
between case status and exposure to environmental che-
micals. Each chemical was assessed in 2 different uni-
variate models: once as a continuous variable, and once as
adichotomizedvariable.Forthelatter,wedichotomizedat
the median. We also assessed these relationships in multi-
variable models that were adjusted for age at enrolment,
ethnicity, smoking and alcohol use history, family history
of breast cancer, number of live births, number of months
of breastfeeding children, menopausal status, and hor-
mone use history. P-value B0.05 was considered statisti-
cally significant.
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During enrolment, of the approximately 470 women who
visited the surgery clinic for breast-related health issues,
203 were enrolled into the study. This paper presents
results of serum and urine samples collected at the time of
enrolment,limitedtothe170women(75cases,95controls)
for whom we had sufficient quantities for laboratory
analyses. The 33 women who were excluded from analyses
did not differ with respect to demographic variables from
the 170 women who were included (data not shown).
Descriptive characteristics are shown in Table I. Age at
enrolment ranged from 30 to 88 years, with a mean age of
51 years. Women of Eskimo (54.7%), Indian (21.8%), and
Aleut (15.9%) ethnicities were represented. All 5 regions
of the state were represented within the study population.
The majority (58.2%) of participants resided in Alaska’s
south central region at the time of enrolment. The fewest
lived in the southeast (5.9%) and the interior (1.2%)
regions. Almost one-fifth (17.6%) of women reported a
family history of breast cancer. Almost all (92.4%) of the
women reported having children. A history of smoking
was reported by 77.6% of the women; however, at the
time of enrolment, only 59.3% of respondents were
current smokers. Similarly, 90% of the women reported
ever drinking alcohol, but only 51.3% of respondents
reported any alcohol use at the time of enrolment.
Case women reported a significantly lower median
cumulative number of months of breast feeding (2
months) than control women (8 months). The variable
‘‘expecting moreperiods’’ wasused as aproxy measurefor
menopausal status   women who responded ‘‘no’’ were
assumed to be menopausal. More case women (63.9%)
responded ‘‘no, they were not expecting more menstrual
periods’’ than control women (45.6%). That is, more case
women were menopausal than control women, a statisti-
cally significant difference (p 0.03). No other descriptive
variables differed significantly between cases and controls.
Sixty-two of 75 (83%) case women had invasive cancer
tumours. We compared the descriptive characteristics and
known risk factors for breast cancer shown in Table I
between case women with invasive vs. non-invasive
cancers and found no significant differences between
them for these variables (data not shown).
GM concentrations and confidence intervals for per-
sistent pesticides, indicator PCBs, and BDE-47 measured
in serum, and phthalate metabolites measured in urine
are shown in Table II. GM serum concentrations of most
pesticides were lower in case women than in controls.
Only gamma (g)-hexachlorocyclohexane was higher in
cases (8.3 ng/g lipid) than controls (7.7 ng/g lipid);
however, this difference was not statistically significant.
The GM serum concentrations of all 3 indicator PCBs
were also lower among cases than controls, although
again, these differences were not statistically significant.
The GM serum concentration of BDE-47 was statistically
significantly higher in case women (38.84 ng/g lipid)
than in controls (25.11 ng/g lipid) (p 0.04). Although
GM urinary concentrations for most of the 7 phthalate
metabolites were higher among cases than controls, these
differences were not statistically significant.
Results of the univariate logistic regression analyses
showed no association between the median concentra-
tions of persistent pesticides, PCBs, or most of the
phthalate metabolites and breast cancer status (Table
III). However, urinary concentrations above the median
ofmono-(2-ethylhexyl)phthalate(MEHP)wereassociated
with breast cancer, and the association was statistically
significant in both univariate and multivariable analyses
(OR2.16,95%CI1.16 4.05,p 0.02andORadj2.43,95%
CI 1.13 5.25, p 0.02, respectively). The result of uni-
variate logistic regression analysis of BDE-47 approached
statistical significance (OR 1.79, 95% CI 0.97 3.32;
p 0.06). However, this association was not statistically
significant in the multivariable analysis. Conversely, the
result of the same analysis for p,p?-DDTsuggested a slight
protectiveeffect(OR0.55,95%CI0.30 1.01,p 0.05).No
significant associations between continuous concentra-
tions of environmental chemicals and breast cancer status
were found.
Of the 62 women who had invasive tumours, 40 (65%)
had tumours that were positive for both oestrogen- and
progesterone-binding capacity (ER /PR ), while 13
(17.3%) were negative for both hormone markers (ER /
PR ). Women with ER /PR  tumours (n 13) had GM
serum concentrations of persistent pesticides, PCBs, and
BDE-47thatwereconsistently(7.7 48%)higher,although
not significantly different, than women with ER /PR 
tumours(n 40).Urineconcentrationswerehigher in3of
7 phthalate metabolites among women with ER /PR 
tumours. The differences were not statistically significant
(Table IV). We estimated the odds ratios for the ER and
ER  groups, modelling the probability of ER . While
results for MEHP were not significant, the estimates
indicated a positive association.
Discussion
The scientific literature contains conflicting reports about
the association between exposure to persistent organic
pollutants and breast cancer (4 16). Results of some
studies demonstrated an association between the DDT
metabolite DDE and breast cancer (7 9), while others
did not (10 14). Studies of exposure to PCBs and
breast cancer incidence also reported conflicting results
(7 9,12,15,16). Few studies have focused on the associa-
tion between exposure to environmental contaminants
andbreastcancerspecificallyamongANwomen,andonly
one epidemiologic study was found that examined the
relation between PBDE and breast cancer in any popula-
tion (21). Rubin et al. (4) confirmed DDT and PCB
exposure in AN women, but did not find that exposuresto
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Total
a Case Control p
b
Number of women 170 75 95  
Mean age at enrolment in years (range) 51 (30 88) 53 (30 78) 50 (30 88) 0.08
Mean age at menarche in years (range) 13 (9 19) 13 (9 19) 13 (10 17) 0.68
Result n (%)
Ethnicity
Eskimo 93 (54.7) 36 (48.0) 57 (60.0) 0.06
Indian 37 (21.8) 22 (29.3) 15 (15.8)
Aleut 27 (15.9) 9 (12.0) 18 (19.0)
Other 13 (7.6) 8 (10.7) 5 (5.3)
Service units by region at birth
South central (Anchorage) 33 (19.6) 15 (20.3) 18 (19.1) 0.08
Interior (Fairbanks) 8 (4.8) 3 (4.1) 5 (5.3)
Northwest (Barrow, Kotzebue, Nome) 46 (27.4) 17 (23.0) 29 (30.9)
Southwest (Bethel & Dillingham) 44 (26.2) 16 (21.6) 28 (29.8)
Southeast (Sitka Mt. Edgecumbe; Annette Isl) 17 (10.1) 13 (17.6) 4 (4.3)
Other 20 (12.0) 10 (13.5) 10 (10.6)
Service units by region at time of enrolment
South central (Anchorage) 99 (58.2) 42 (56.0) 57 (60.0) NA
Interior (Fairbanks) 2 (1.2) 1 (1.3) 1 (1.0)
Northwest (Barrow, Kotzebue, Nome) 32 (18.8) 14 (18.7) 18 (19.0)
Southwest (Bethel & Dillingham) 26 (15.3) 7 (9.3) 19 (20.0)
Southeast (Sitka Mt. Edgecumbe; Annette Isl) 10 (5.9) 10 (13.3) 0
Other 1 (0.6) 1 (1.3) 0
Highest education level completed
58th grade 27 (15.9) 11 (14.7) 16 (16.8) 0.45
9th 11th 18 (10.6) 5 (6.7) 13 (13.7)
High school graduate 109 (64.1) 52 (69.3) 57 (60.0)
]College graduate 16 (9.4) 7 (9.3) 9 (9.5)
Smoking (yes)
Ever 132 (77.7) 62 (82.7) 70 (73.7) 0.20
Current (n 135) 80 (59.3) 33 (51.6) 47 (66.2) 0.11
Alcohol (yes)
Ever 153 (90.0) 71 (94.7) 82 (86.3) 0.08
Current (n 154) 79 (51.3) 34 (47.9) 45 (54.2) 0.52
Family history of breast cancer (yes)
Mother 7 (4.1) 3 (4.0) 4 (4.2) 0.58
Maternal grandmother 7 (4.1) 4 (5.3) 3 (3.2) 0.29
Paternal grandmother 4 (2.4) 2 (2.7) 2 (2.1) 0.91
Sister 10 (5.9) 3 (5.0) 7 (9.1) 0.51
Daughters 2 (1.2) 0 2 (2.9) 0.50
Pregnancies (yes)
Ever (n 169) 158 (93.5) 71 (96.0) 87 (91.6) 0.35
Live births
Median # births (range) 3 (0 11) 3 (0 10) 3 (0 11) 0.77
Number of women (%) 157 (92.4) 71 (96.0) 86 (90.5) 0.23
Breast fed
Median cumulative months (range) 4 (0 216) 2 (0 88) 8 (0 216) 0.05
Number of women (%) 106 (62.4) 45 (60.0) 61 (64.2) 0.63
Hormone history (yes)
Ever birth control pills 111 (66.9) 49 (65.3) 62 (68.1) 0.74
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study did not include PBDEs or phthalates. Day et al. (32)
suggested that increases of breast cancer among AN
women over the past 30 years may be attributable to
increased body mass index (BMI) and a shift away from a
traditional diet.
We believe this is the first study to measure and report
PBDE serum concentrations among AN women and the
first to suggest a possible association between breast
cancer and PBDE exposure in this population. The serum
concentrations of BDE-47 measured in our participants
ranged from 0.71 to 1,370 ng/g lipid, and the GM
concentration of BDE-47 was 30.4 ng/g lipid (95% CI
24.9 37.2). AN women have GM serum concentrations
of BDE-47 similar to concentrations previously reported
in studies from other areas of the Unites States.
A representative sample of US women (22) had a lipid-
adjusted GM serum BDE-47 concentration of 19.6 ng/g
lipid (95% CI 16.4 23.5). AN women in our study
had GM concentrations of BDE-47 that more closely
Table I (Continued)
Total
a Case Control p
b
Ever hormones 62 (36.9) 25 (33.8) 37 (39.4) 0.52
Menopausal status (yes)
# Women not expecting more periods/who are
menopausal (%)
87 (53.7) 46 (63.9) 41 (45.6) 0.03
aDue to missing responses, sums do not always equal to 170. Where this was the case, percentages were calculated using the number of
women answering the question.
bP-values represent comparison between cases and controls, using t-tests for means of continuous variables, Wilcoxon 2-sample test for
medians of continuous variables, and Chi-square tests for categorical variables.
Table II. Geometric mean serum concentrations (lipid adjusted), 95% conﬁdence intervals, and p-values of selected persistent
pesticides, polychlorinated biphenyls (PCB), and polybrominated diphenyl ethers (PBDE), and urinary concentrations (mg/g creatinine)
of phthalate metabolites in a population of Alaska Native women: 1999 2002
Geometric mean (ng/g lipid) (95% confidence interval)
Analyte Total (N 170) Case (N 75) Control (N 95) p
Persistent pesticides (ng/g lipid)
p,p?-Dichlorodiphenylethylene (DDE) 3,912 (3,372 4,539) 3,866 (3,103 4,866) 3,944 (3,229 4,817) 0.91
Hexachlorobenzene 404 (340 480) 340 (270 433) 464 (365 590) 0.08
Mirex 39.9 (33.3 47.8) 33.1 (25.8 42.5) 45.6 (35.5 59.2) 0.08
Oxychlordane 241 (200 290) 215 (166 276) 265 (200 347) 0.28
b-Hexachlorocyclohexane 151 (126 180) 143 (110 183) 158 (123 202) 0.57
g-Hexachlorocyclohexane 8.02 (7.60 8.47) 8.33 (7.77 8.94) 7.77 (5.99 8.50) 0.23
o,p?-Dichlorodiphenyltrichloroethane (DDT) 15.6 (14.1 17.3) 15.0 (13.1 17.3) 16.1 (13.9 18.7) 0.51
p,p?-DDT 62.8 (55.0 71.8) 56.3 (46.5 68.0) 68.7 (56.8 82.3) 0.16
trans-Nonachlor 344 (282 420) 302 (226 403) 380 (290 503) 0.27
Polychlorinated biphenyls (ng/g lipid)
138/158 413 (347 491) 386 (304 490) 436 (340 558) 0.50
153 590 (494 705) 541 (424 689) 632 (491 815) 0.39
180 345 (297 401) 325 (266 398) 362 (291 450) 0.49
Polybrominated diphenyl ether (ng/g lipid)
47 30.4 (24.9 37.2) 38.8 (28.6 52.7) 25.1 (19.3 32.7) 0.04
Phthalate metabolites (mg/g creatinine)
Mono-butyl phthalate (MBP) 15.9 (13.3 19.1) 14.6 (10.7 19.8) 17.1 (13.8 21.2) 0.41
Mono-benzyl phthalate (MBzP) 7.1 (6.1 8.4) 7.6 (5.8 10.0) 6.7 (5.6 8.2) 0.46
Mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) 32.8 (27.7 38.9) 36.4 (27.6 48.0) 30.1 (24.4 37.2) 0.28
Mono-(2-ethylhexyl) phthalate (MEHP) 4.2 (3.3 5.4) 5.3 (3.6 7.7) 3.5 (2.6 4.7) 0.10
Mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP) 21.9 (18.7 25.7) 24.3 (18.8 31.5) 20.1 (16.4 24.5) 0.24
Mono-ethyl phthalate (MEP) 57.4 (45.8 71.9) 50.5 (36.4 70.0) 63.8 (46.8 87.0) 0.31
Mono-methyl phthalate (MMP) 1.7 (1.4 2.1) 1.7 (1.3 2.3) 1.7 (1.4 2.2) 0.98
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ng/g lipid; 95% CI 31.8 46.4) of the US sample (22).
BDE-47 concentrations measured in 50 serum samples
collected in the 1990s from Laotian women living near
San Francisco ranged from less than the LOD (10 ng/g
lipid) to 511 ng/g lipid (mean 50.6 ng/g lipid; median 16.5
ng/g lipid) (33). The concentration of BDE-47 measured
in a 2005 study of pooled serum from 100 discarded
anonymous US samples collected in 2003 was 32.5 ng/g
lipid (34).
A recent case control study that measured concentra-
tions of the 5 major PBDE congeners, including BDE-47,
in adipose tissue collected from 134 women in the San
Francisco Bay Area found no association between ex-
posure to PBDEs and breast cancer (21). In that study
population, the median concentration of BDE-47 mea-
sured in adipose was 22.0 ng/g lipid. For case women, the
concentration was 18.83 ng/g lipid, and for control
women, it was 26.85 ng/g lipid. The authors state that
these adipose concentrations of PBDE were among the
highest ever reported. The GM concentrations of BDE-
47 measured in serum in our study population (30.4 ng/g
lipid) and among our case women (38.8 ng/g lipid,
respectively) were higher than concentrations reported
in adipose.
The results of our study suggest a possible association
between breast cancer and BDE-47 (OR 1.79, p 0.06).
However, the association is not supported in a multi-
variable analysis of BDE-47 with other known risk factors
including age, menopause status, and having a relative
with breast cancer. Our data seem to show a protective
effect from exposure to p,p? DDT. This association has
notbeenreportedpreviously.Itispossiblethat theresult is
spurious, and should be interpreted with care.
No reports describing phthalate exposure among AN
people were found in the literature. Our results suggested
an association between urinary concentrations dichoto-
mized at the median of the phthalate metabolite MEHP
and breast cancer, an association that held in both
univariate and multivariable analyses. However, MEHP
is a minor metabolite of DEHP, and is the metabolite
from which all others are formed. Therefore, we would
expect to see associations with the other metabolites as
well. The fact that associations were not found among the
other DEHP metabolites may suggest the association
between MEHP and breast cancer is a chance finding.
Table III. Univariate and multivariable odds ratios (OR), 95% conﬁdence intervals, and p-values for the association between breast
cancer and selected persistent pesticides, polychlorinated biphenyls (PCB), polybrominated diphenyl ethers (PBDE), and phthalate
metabolites among Alaska Native women   1999 2002
Analyte
Univariate OR
(95% confidence interval) p-value
Multivariable OR
(95% confidence interval) p-value
Persistent pesticides
p,p?-Dichlorodiphenylethylene (DDE) 1.05 (0.57 1.92) 0.88 0.60 (0.26 1.43) 0.25
Hexachlorobenzene 0.78 (0.43 1.44) 0.44 0.47 (0.19 1.16) 0.10
Mirex 0.82 (0.45 1.50) 0.55 0.65 (0.28 1.55) 0.33
Oxychlordane 1.05 (0.57 1.92) 0.88 0.91 (0.35 2.35) 0.84
b-Hexachlorocyclohexane 1.19 (0.65 2.18) 0.58 1.21 (0.44 3.31) 0.71
g-Hexachlorocyclohexane 1.70 (0.92 3.12) 0.09 1.88 (0.88 4.03) 0.10
o,p?-Dichlorodiphenyltrichloroethane (DDT) 0.99 (0.54 1.82) 0.99 1.00 (0.48 2.11) 1.00
p,p?-DDT 0.55 (0.30 1.01) 0.05 0.49 (0.22 1.10) 0.08
trans-Nonachlor 0.98 (0.53 1.80) 0.95 0.65 (0.26 1.66) 0.37
Polychlorinated biphenyls
138/158 0.95 (0.52 1.75) 0.88 0.64 (0.27 1.52) 0.31
153 0.95 (0.52 1.75) 0.88 0.55 (0.22 1.41) 0.21
180 0.87 (0.47 1.59) 0.64 0.43 (0.17 1.09) 0.08
Polybrominated diphenyl ether
47 1.79 (0.97 3.32) 0.06 1.58 (0.75 3.33) 0.23
Phthalate metabolites
Mono-butyl phthalate (MBP) 0.78 (0.43 1.45) 0.44 0.66 (0.32 1.39) 0.28
Mono-benzyl phthalate (MBzP) 1.22 (0.66 2.25) 0.52 1.53 (0.73 3.22) 0.26
Mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) 1.28 (0.69 2.35) 0.44 1.50 (0.71 3.17) 0.28
Mono-(2-ethylhexyl) phthalate (MEHP) 2.16 (1.16 4.05) 0.02 2.43 (1.12 5.24) 0.02
Mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP) 0.95 (0.52 1.76) 0.88 1.15 (0.54 2.44) 0.71
Mono-ethyl phthalate (MEP) 0.71 (0.39 1.31) 0.28 0.55 (0.26 1.18) 0.13
Mono-methyl phthalate (MMP) 0.95 (0.52 1.76) 0.88 0.86 (0.40 1.85) 0.70
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were measured in a single spot urine sample. Urinary
concentrations of some phthalate metabolites, including
MEHP, can be highly variable over time (35). Although
this variability could result in exposure misclassification,
it would likely be non-differential with respect to the
outcome examined, significantly reducing our ability to
observe an effect of DEHP on cancer risk. For these
reasons, the findings regarding MEHP should be inter-
preted with caution.
We found only one study that reported an association
between exposure to phthalates and breast cancer (23).
A case control study of more than 450 Mexican women
found that case women had higher concentrations (169.58
mg/g creatinine) of the phthalate metabolite MEP than did
control women (106.78 mg/g creatinine)   concentrations
that were almost double those of MEP among our study
population   and that MEP concentrations were asso-
ciated with breast cancer.
A recent in vitro study implicated phthalates as possible
potentiators in breast carcinogenesis (36). One study
examined the effect of 2 phthalates   neither of them
MEHP   on ER-negative breast cancer cells. The authors
reported that the exposure induced cell proliferation,
migration, invasion, and tumour formation (37). Animal
studies have demonstrated metabolic differences between
species, necessitating human studies to determine health
effects (22,29). Temporal differences in human exposure,
inconsistent studydesign, and differing methods,however,
appear to account for wide variability in findings reported
from studies investigating human health effects of phtha-
late exposure (22,35,38).
It is widely accepted that oestrogen is an important
contributor to breast cancer development and progression
(39),aneffectdemonstratedbestinstudiesofbreastcancer
among males; men who develop breast cancer have higher
thannormallevelsofoestrogen(40).Reproduction-related
characteristics, such as early age at menarche, later age at
bearing first child, and postmenopausal obesity are
associated with ER  tumours, which respond to treat-
ment with hormone therapy(41,42). ER  tumours arenot
influenced by oestrogen and do not respond to treatment
by hormone therapy, are associated with higher mortality
(43), and are believed by some to have different promoters
Table IV. Geometric mean serum concentrations (ng/g lipid) of selected persistent pesticides, polychlorinated biphenyls (PCB), and
polybrominated diphenyl ethers (PBDE), and urinary concentrations (mg/g creatinine) of phthalate metabolites in a population of
Alaska Native women with speciﬁc tumour hormone receptor status   1999 2002
Geometric mean (95% confidence interval)
ER /PR  cases (n 40) ER /PR  cases (n 13) p
Persistent pesticides
p,p?-Dichlorodiphenylethylene (DDE) 3,103 (2,231 4,316) 4,273 (2,566 7,115) 0.31
Hexachlorobenzene 290 (200 420) 441 (240 804) 0.25
Mirex 26.8 (18.7 38.5) 40.9 (18.2 91.8) 0.27
Oxychlordane 166 (113 242) 273 (134 556) 0.19
b-Hexachlorocyclohexane 110 (74 162) 185 (103 334) 0.16
g-Hexachlorocyclohexane 7.92 (7.24 8.76) 8.58 (6.69 11.02) 0.49
o,p?-Dichlorodiphenyltrichloroethane (DDT) 13.9 (11.3 17.1) 17.0 (11.7 24.5) 0.35
p,p?-DDT 49.4 (37.0 66.7) 66.0 (40.9 108) 0.32
trans-Nonachlor 217 (141 337) 416 (192 907) 0.13
Polychlorinated biphenyls
138/158 327 (237 455) 503 (270 925) 0.19
153 424 (296 614) 672 (340 1326) 0.22
180 273 (202 372) 354 (198 626) 0.41
Polybrominated diphenyl ethers
47 34.1 (21.3 54.1) 51.9 (23.1 116.8) 0.36
Phthalate metabolites
Mono-butyl phthalate (MBP) 15.3 (9.0 26.1) 12.8 (6.7 24.8) 0.71
Mono-benzyl phthalate (MBzP) 8.3 (5.4 12.8) 6.2 (3.1 12.7) 0.51
Mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) 35.5 (24.5 51.4) 49.4 (20.7 119.1) 0.40
Mono-(2-ethylhexyl) phthalate (MEHP) 4.6 (2.8 7.6) 11.1 (3.7 33.8) 0.10
Mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP) 23.3 (16.8 32.5) 36.6 (16.1 83.9) 0.21
Mono-ethyl phthalate (MEP) 49.6 (32.3 76.1) 47.7 (23.0 98.9) 0.93
Mono-methyl phthalate (MMP) 1.54 (1.1 2.2) 1.48 (0.5 4.4) 0.95
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gicstudybasedoncountylevelbreastcancerandexposure
dataconcluded that ER tumourscould beinfluenced by
environmental factors with endocrine disrupting capabil-
ities (44). Høyer et al., in a nested case control study of
Danish women, concluded the opposite: that exposure to
potential estrogenic organochlorines does not lead to
developing ER  breast cancer type. This study further
reported an association between dieldrin and incidence of
ER  tumours (46). Although the differences were not
statistically significant, in our study, women with ER /
PR  tumours type had consistently higher concentrations
ofthepersistentpesticideswemeasured,thanER /PR 
women.
Limitations of this study included a small sample size,
which may have decreased our power to detect statistical
differences, and the inability to include all potential con-
founders (e.g. BMI) in the analyses. Another limitation is
the potential exposure misclassification due to the short
half-lifeofphthalates,whichcanresultinhighvariabilityof
phthalate metabolites, particularly MEHP (35). However,
any residual misclassification would be non-differential
and bias results towards the null. Furthermore, our
controls were women with benign breast disease. It is
possible that one or more of the environmental chemicals
we measured could be associated with benign breast
disease, along with breast cancer. This could have resulted
in some of our null findings. Future research should
attempt to measure environmental chemical exposures in
the general AN population.
Conclusion
AN women may be exposed to types and concentrations
of environmental chemicals that are different from other
populations of women in the US. Studies of DDTor PCBs
have not demonstratedwith any certainty that exposure to
these chemicals results in increased risk of developing
breast cancer. The health effects of exposure to relatively
new environmental chemicals, such as PBDE and phtha-
lates, are not well understood. The biologic plausibility
exists for these chemicals to affect reproductive and other
hormonally-regulated systems, as they are known endo-
crine disruptors. Larger population-based studies of AN
people would provide more statistical power to better
determine possible association between exposure to con-
taminants, in particular those with endocrine disrupting
capabilities, and the risk of breast cancer.
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